Breaking News

Metrics Appoints CFO

August 2, 2013

Edwards to oversee financial, logistical and HR ops

Wes Edwards, MBA, CPA, has been appointed chief financial officer at Metrics Inc. Mr. Edwards has 15 years of corporate and military experience in finance, accounting, supply chain management and pricing. He will oversee the company’s financial, logistical and human resources operations. Following the acquisition by the publicly traded Mayne Pharma Group last year, Metrics now interacts with newfound stakeholders, including regulators and investors.
Prior to joining the company, Mr. Edwards was the controller and finance director of two affiliated divisions of MBM Customized Foodservice Distribution, which was acquired by McLane Co., Inc. At MBM, Mr. Edwards was responsible for a team of finance, accounting and information technology professionals supporting all aspects of financial analysis and execution, cash and risk management, internal control and external GAAP compliance.
“Wes has significant expertise when it comes to operating in public companies, along with a deep appreciation for organizational integrity and performance, which makes his coming onboard at Metrics timely and useful,” said Phil Hodges, president of Metrics. “I know he’ll apply his knowledge in ways that help protect the company’s assets and deliver superior financial results.”

Related Contract Manufacturing:

Related Packaging:

  • Packaging Equipment Close-Up

    Packaging Equipment Close-Up

    Kristin Brooks, Contract Pharma||March 9, 2016
    To meet the wide-ranging needs of the marketplace, suppliers and contract packagers are looking to deliver flexible solutions.

  • Top 25 Pharma and Biopharma Report

    Top 25 Pharma and Biopharma Report

    July 20, 2015
    (Based on 2014 Sales, in $U.S. Millions)

  • Driving Innovation Through Contracting

    Driving Innovation Through Contracting

    David Agrella, Bryan Haas, Pharm.D., Timothy King, Dr.P.H. and Scott Maisto , PPD||November 13, 2014
    This article discusses the advantages to both biopharmaceutical companies and their vendors of moving outsourcing spend to a commercial model focused on the desired deliverable and not the level of effort required to achieve the deliverable.